Noxopharm Publishes in Nature Immunology Validating Sofra Immune Tech Platform
Noxopharm Limited is a clinical-stage Australian biotech company dedicated to pioneering innovative treatments in cancer, inflammation, and mRNA vaccine technologies. Founded with a mission to address some of the most challenging medical conditions, the company focuses on developing novel therapeutic solutions through its two proprietary technology platforms: Sofra™ and Chroma™.
The Sofra™ technology platform is a groundbreaking approach that leverages oligonucleotides to develop potential treatments for autoimmune and inflammatory diseases, as well as enhance mRNA vaccine effectiveness. Meanwhile, the Chroma™ platform is specifically focused on developing multiple drug candidates primarily targeting cancer treatment. The company’s lead clinical drug candidate, Veyonda®, is currently undergoing a phase 1 investigator-initiated clinical trial exploring combination therapy with immunotherapy for cancer treatment.
Led by CEO Dr. Gisela Mautner, Noxopharm is distinguished by its strategic approach to drug development, which combines in-house expertise with collaborative partnerships with leading researchers. The company’s commitment to innovative science aims to create life-changing therapies that have the potential to improve patient outcomes in complex and challenging disease areas, particularly in oncology and inflammatory conditions. By pushing the boundaries of medical research, Noxopharm seeks to develop transformative treatments that address critical unmet medical needs.
© 2026 StockWire X Pty Ltd. All rights reserved.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.